← Back to patent-cliff list
Muparfostat sodium
Tier C — Watch / tradeMuparfostat sodium
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGF2, FGF1, VEGFA
Indications (approved)：Hepatocellular carcinoma, Liver cancer, Solid tumour, Lung cancer, 皮肤黑色素瘤, Prostate cancer, Melanoma, Non-small cell lung cancer
Regional status
US
Discontinued
2007-12-01
EU
Discontinued
2007-12-01
China
Phase III
2011-08-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Muparfostat sodium?
Approved indications include: Hepatocellular carcinoma, Liver cancer, Solid tumour, Lung cancer, 皮肤黑色素瘤, Prostate cancer, Melanoma, Non-small cell lung cancer.
When does the Muparfostat sodium patent expire?
No public expiry year is available for Muparfostat sodium yet; this page updates once verified.
How do I get a quote for Muparfostat sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22